A5027312193- Antifungal resistance and susceptibility
- COVID-19 Clinical Research Studies
- Fungal Infections and Studies
- Immunotherapy and Immune Responses
- Nosocomial Infections in ICU
- Breast Cancer Treatment Studies
- Viral gastroenteritis research and epidemiology
- Disaster Response and Management
- Radiopharmaceutical Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Trauma and Emergency Care Studies
- Parasitic Diseases Research and Treatment
- Biosimilars and Bioanalytical Methods
- Sepsis Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Cardiac Arrest and Resuscitation
- Antibiotic Use and Resistance
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Economic and Financial Impacts of Cancer
- Cystic Fibrosis Research Advances
- SARS-CoV-2 and COVID-19 Research
- Pharmaceutical studies and practices
- Clostridium difficile and Clostridium perfringens research
- Cell Adhesion Molecules Research
University Hospital Cologne
2022-2025
University of Cologne
2022-2025
Heinrich Heine University Düsseldorf
2024
Düsseldorf University Hospital
2024
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
2024
QUIRIS Healthcare
2020-2023
Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive economically challenging healthcare systems. Cost analyses drugs against candidiasis, such as rezafungin, thus great interest to payers.We conducted a cost-of-illness study patients with infections based on real-word data Department I Internal Medicine, University Hospital Cologne (Germany) between 2016 2021. Health-economic parameters were analysed...
Renal insufficiency is one of the most common complications in treatment multiple myeloma (MM). The administration isatuximab showed improved patient outcome regarding occurrence renal insufficiency. Building on results ICARIA-MM study, aim this study was to quantify potential cost savings due a prevented progress Real-life accounting data University Hospital Cologne (Germany) inpatients with MM between 2016 and 2020 were analyzed presence health-economic impact less severe filtration German...
Background Despite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing SARS-CoV-2 infections; however, data on B- and T-cell responses lacking. While vaccination schedules general population have defined, achieving immunogenicity who remains a challenge. Objective The primary objective is analyze anti-spike–immunoglobulin G (IgG) titers after repeated messenger ribonucleic...
Abstract Purpose First detected in China 2019, the novel coronavirus disease (COVID-19) has rapidly spread globally. Since then, healthcare systems are exposed to major challenges due scarce personnel and financial resources. Therefore, this analysis intended examine treatment costs of COVID-19 inpatients a German single centre during first pandemic wave 2020 from payer perspective. Potential cost savings were assessed considering administration remdesivir according European Medicines Agency...
In the past decades, highly innovative treatments in field of diffuse large B-cell lymphoma (DLBCL) became available clinical practice. The aim this study was to assess cost-benefit relation third-line interventions DLBCL from a German payer perspective.Clinical benefit allogeneic stem cell transplantation (alloSCT), chimeric antigen receptor T cells therapy (CAR T) [tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel)] best supportive care (BSC) assessed terms median overall...
Summary Background Isavuconazole (ISA) is a frequently used antifungal agent for the treatment of invasive fungal diseases (IFDs). However, hospital reimbursement data ISA limited. Objectives The primary objective this study was to analyse different perspectives relevant stakeholders and (dis)incentives administration in Germany. To that aim, health economic effects using from management perspective were analysed. Patients/Methods Based on principal‐agent theory (PAT), (a) patient...
Multidrug-resistant Gram-negative bacteria (MDR-GNB) cause serious infections and aggravate disease progression. Last resort antibiotics are effective against MDR-GNB reimbursed by flat rates based on German diagnosis-related groups (G-DRG). From a hospital management perspective, this analysis compared reimbursement for last with their acquisition costs to outline potential funding gaps. Retrospective analyses medical charts real-life data included patients pneumonia due treated in...
Abstract Background Triple-negative breast cancer (TNBC) is responsible for 10–20% cases of and resulting in rising healthcare costs. Thus, health-economic evaluations are needed to relate clinical outcomes costs treatment options provide recommendations action from a perspective. Methods We investigated the cost-benefit-ratio approved metastatic TNBC Germany by applying efficiency frontier approach. These included sacituzumab-govitecan (SG), eribulin, vinorelbine, capecitabine. Clinical...
Abstract Background Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length stay and additional treatment costs. Bezlotoxumab, first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention after randomized clinical trials demonstrated its superior efficacy vs. placebo. Methods The budget impact analysis at hand focused on patients high risk CDI recurrence. Treatment with standard care (SoC) +...
Internationally, healthcare systems are confronted by an ever-increasing scarcity of medical resources due to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. The aim this study was investigate impact remdesivir on demand hospital bed capacities for hospitalized COVID-19 patients and evaluate potentially created treating additional or elective treatments at hospital.An epidemiological model developed that utilized population Cologne (Germany) during first wave (first...
Invasive fungal diseases (IFD) are life-threatening and demand timely appropriate treatment. Research showed that isavuconazole treatment positively affects clinical outcome length of hospital stay (LOS).The aim this study was to assess the costs patients diagnosed with IFD treated using real-world data from a German cancer centre.Data LOS collected Jan-2016 Jun-2021 at Department I Internal Medicine, University Hospital Cologne were retrieved. Case-related resources consumed during across...
<sec> <title>BACKGROUND</title> Despite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing SARS-CoV-2 infections; however, data on B- and T-cell responses lacking. While vaccination schedules general population have defined, achieving immunogenicity who remains a challenge. </sec> <title>OBJECTIVE</title> The primary objective is analyze anti-spike–immunoglobulin G (IgG)...
Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of innovative pharmaceutical isavuconazole in inpatient setting Germany (Bismarck-based healthcare system). Little is known about reimbursement pharmaceuticals Beveridge-based systems.The aim this study was to evaluate market access process and isavuconazole, exemplary pharmaceuticals, England Spain.Market processes both countries were described. Focussing on typical patient clusters treatment, data regarding inpatients with...
Background: Booster vaccination for the elderly provides protection from severe SARS-CoV-2 infection, however data is still limited on optimal timing, dosing and immunogenicity in this population.Methods: EU-COVAT-1-AGED Part B a randomised controlled, adaptive, multicentre, phase II trial evaluating safety of 4th (2nd booster) individuals ≥75 years. Participants were to receive either BNT162b2 (Comirnaty®, 30µg) or mRNA-1273 (Spikevax®, 100µg). The primary endpoint was rate 2-fold antibody...